Checkpoint inhibitor-induced uveitis: a case series

被引：59

作者：

Conrady, Christopher D. ^{[1
]}

Larochelle, Marissa ^{[1
]}

Pecen, Paula ^{[2
]}

Palestine, Alan ^{[2
]}

Shakoor, Akbar ^{[1
]}

Singh, Ajay ^{[3
]}

机构：

[1] Univ Utah, Dept Ophthalmol, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA

[2] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO 80045 USA

[3] Univ Kansas, Sch Med, Dept Ophthalmol, Kansas City, KS 66160 USA

来源：

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2018年 / 256卷 / 01期

关键词：

Checkpoint inhibitors; Metastatic cancer; Autoimmune uveitis; BLOCKADE; CANCER; AUTOIMMUNITY; APOPTOSIS; DEFICIENT; MECHANISM; CTLA-4; BRAF;

D O I：

10.1007/s00417-017-3835-2

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs. Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers. All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease. Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist.

引用

页码：187 / 191

页数：5

共 22 条

[1]

[Anonymous], RETIN CASES BRIEF RE

[2] A look at autoimmunity and inflammation in the eye [J].

Caspi, Rachel R. .

JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (09) :3073-3083

[3] Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib [J].

Choe, Christina H. ;

McArthur, Grant A. ;

Caro, Ivor ;

Kempen, John H. ;

Amaravadi, Ravi K. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 158 (04) :831-837

[4] CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction [J].

Contardi, E ;

Palmisano, GL ;

Tazzari, PL ;

Martelli, AM ;

Falà, F ;

Fabbi, M ;

Kato, T ;

Lucarelli, E ;

Donati, D ;

Polito, L ;

Bolognesi, A ;

Ricci, F ;

Salvi, S ;

Gargaglione, V ;

Mantero, S ;

Alberghini, M ;

Ferrara, GB ;

Pistillo, MP .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (04) :538-550

[5]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[6] Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib [J].

Draganova, Dafina ;

Kerger, Joseph ;

Caspers, Laure ;

Willermain, Francois .

JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2015, 5

[7] Branch retinal artery occlusion associated with posterior uveitis [J].

Kahloun R. ;

Mbarek S. ;

Khairallah-Ksiaa I. ;

Jelliti B. ;

Yahia S.B. ;

Khairallah M. .

Journal of Ophthalmic Inflammation and Infection, 3 (1) :1-5

[8] Bilateral Anterior Uveitis Associated with Nivolumab Therapy [J].

Karlin, Justin ;

Gentzler, Ryan ;

Golen, Jeffrey .

OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (02) :283-285

[9] Molecular basis of T cell inactivation by CTLA-4 [J].

Lee, KM ;

Chuang, E ;

Griffin, M ;

Khattri, R ;

Hong, DK ;

Zhang, WG ;

Straus, D ;

Samelson, LE ;

Thompson, CB ;

Bluestone, JA .

SCIENCE, 1998, 282 (5397) :2263-2266

[10] Toxicity management of immunotherapy for patients with metastatic melanoma [J].

Linardou, Helena ;

Gogas, Helen .

ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (14)

← 1 2 3 →